2,6-Ditert-butyl-3-[(2-ethyl-1,1-dioxo-1,2-thiazolidin-3-ylidene)methyl]phenol

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,6-Ditert-butyl-3-[(2-ethyl-1,1-dioxo-1,2-thiazolidin-3-ylidene)methyl]phenol
• 英文别名: 2,6-ditert-butyl-3-[(2-ethyl-1,1-dioxo-1,2-thiazolidin-3-ylidene)methyl]phenol
• 化学式: C₂₀H₃₁NO₃S
• 分子量: 365.5
• InChiKey: GOCRJYYJHFJEEQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  66
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Controlled release pharmaceutical compositions comprising a fumaric acid ester
  申请人：Forward Pharma A/S

  公开号：EP2792349A2

  公开（公告）日：2014-10-22

  The present invention relates to controlled release pharmaceutical compositions comprising a fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.

  本发明涉及包含富马酸酯作为活性物质的控释药物组合物。这些组合物适用于治疗牛皮癣或其他增生性、炎症性或自身免疫性疾病，并能以受控方式释放富马酸酯，从而避免口服后活性物质在胃肠道内的局部高浓度，从而减少与胃肠道相关的副作用。
• CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER
  申请人：Forward Pharma A/S

  公开号：EP3093012A1

  公开（公告）日：2016-11-16

  The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designed to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.

  本发明涉及包含富马酸酯作为活性物质的控释药物组合物。这些组合物适用于治疗牛皮癣或其他增生性、炎症性或自身免疫性疾病，其设计目的是以可控方式释放富马酸酯，从而避免口服后活性物质在胃肠道内的局部高浓度，从而减少与胃肠道相关的副作用。
• TREATMENTS COMPRISING STRONTIUM FOR RHEUMATIC AND ARTHRITIC DISEASES AND PAIN
  申请人：Osteologix A/S

  公开号：EP1758653A2

  公开（公告）日：2007-03-07
• IMPROVING PAIN TREATMENT WITH STRONTIUM COMBINATIONS
  申请人：Osteologix A/S

  公开号：EP1758652A2

  公开（公告）日：2007-03-07
• COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE
  申请人：Urigen Pharmaceuticals, Inc.

  公开号：EP3110427A1

  公开（公告）日：2017-01-04